The β <sub>2</sub> ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome

These findings support the therapeutic potential of formoterol as a new pharmacological strategy for treating Cushing's syndrome and its associated metabolic comorbidities.

Authors

Institutions

Publication Details

Journal
British Journal of Pharmacology
Published
2026-03-04
DOI
https://doi.org/10.1111/bph.70370
Primary Topic
Hormonal Regulation and Hypertension
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome

Kristan H. Cleveland, Lee Jc, Edward D. Parker, Linda Wordeman et al.
British Journal of Pharmacology
Hormonal Regulation and Hypertension
article

The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome

Kristan H. Cleveland, Lee Jc, Edward D. Parker, Linda Wordeman, Kyung-Soon Lee, Juan Jesus Vicente, John D Scott, Devasena Ponnalagu
article en

Abstract

These findings support the therapeutic potential of formoterol as a new pharmacological strategy for treating Cushing's syndrome and its associated metabolic comorbidities.

British Journal of Pharmacology
University of Washington (US)
Good health and well-being
Openalex Percentile: Top 34%
Hormonal Regulation and Hypertension
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.